Despite finally winning a hard-fought FDA approval for its chronic kidney disease (CKD) anemia drug Vafseo last year, Akebia ...

Analysts expect Sun to continue to be more aggressive in chasing speciality assets, but a successful launch is necessary for ...

Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion dis ...

Jay Bhattacharya, nominee for National Institutes of Health director, and FDA pick Marty Makary clear key Senate committee.

The Senate Health, Education, Labor, and Pensions Committee approved Dr. Jayanta Bhattacharya’s nomination to be NIH director ...

The move marks an advancement in reducing plastic waste and assisting global brands in achieving their sustainability ...

Many Americans have started to question the quality of ingredients used within their food, some of which are banned in Europe.

Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.

Financially, Annexon has a strong cash position, providing a runway of 5-8 quarters, but the stock trades almost at cash due ...

High-grade glioma, an aggressive form of pediatric and adult brain cancer, is challenging to treat given the tumor location, ...

The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...

It’s been just six months since Zevra Therapeutics scored an FD | Niemann-Pick disease type C therapy Miplyffa became ...